Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys 11,893 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 11,893 shares of Surrozen stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average price of $19.89 per share, for a total transaction of $236,551.77. Following the transaction, the insider directly owned 1,005,732 shares in the company, valued at $20,004,009.48. The trade was a 1.20% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III bought 18,052 shares of Surrozen stock. The stock was purchased at an average price of $19.60 per share, with a total value of $353,819.20.
• On Friday, January 16th, Group Gp Lp Column III purchased 2,562 shares of Surrozen stock. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $51,240.00.
• On Wednesday, January 14th, Group Gp Lp Column III acquired 5,523 shares of Surrozen stock. The stock was purchased at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III bought 12,470 shares of Surrozen stock. The shares were acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The stock was bought at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III acquired 315,457 shares of Surrozen stock. The stock was bought at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Trading Down 10.1%

NASDAQ:SRZN traded down $2.02 on Tuesday, reaching $17.98. 62,608 shares of the stock traded hands, compared to its average volume of 59,333. The firm has a market capitalization of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The company’s 50 day moving average is $18.98 and its 200-day moving average is $14.13.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. On average, equities research analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC boosted its holdings in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. Geode Capital Management LLC boosted its position in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Surrozen in the 3rd quarter worth about $621,000. Armistice Capital LLC bought a new stake in Surrozen in the second quarter worth about $536,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Surrozen during the 3rd quarter valued at approximately $889,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SRZN has been the topic of several recent analyst reports. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a report on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.